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 Large-scale genome sequencing is poised to provide an exponential increase in the 
discovery of disease-associated mutations, but the functional interpretation of such 
mutations remains challenging.  Here we identify deletions of a sequence termed intestine-
critical region (ICR) on chromosome 16 that cause intractable congenital diarrhea in 
infants.  Transgenic mouse reporter assays show that the ICR contains a regulatory 
sequence that activates transcription during development of the gastrointestinal system.  
Targeted deletion of the ICR in mice caused symptoms recapitulating the human condition.  
Transcriptome analysis uncovered an unannotated open reading frame (Percc1) flanking 
the regulatory sequence whose expression was lost in the developing gut of ICR knockout 
animals.  Targeted deletion of the Percc1 gene in mice caused phenotypes similar to those 
observed upon ICR deletion in mice and patients, whereas an ICR-driven Percc1 transgene 
was sufficient to rescue the phenotypes found in ICR knockout mice.  Taken together, our 
results identify a novel human gene critical for intestinal function and underscore the need 
for targeted in vivo studies for interpreting the growing number of clinical genetic findings 
that do not affect known protein-coding genes. 
In contrast to whole exome sequencing (WES)1, whole genome sequencing (WGS) 
can in principle identify mutations in noncoding sequences, as well as in genes that are not 
annotated in the reference genome.  However, sequence variation affecting poorly 
annotated sequences outside of known genes is challenging to interpret because of the lack 
of structural and functional annotation of these regions.  In the present study, we 
demonstrate how the identification of noncoding deletions in a small number of patients 
coupled to purpose-built mouse models can elucidate the regulatory and genic basis of an 
inherited severe disease (Fig. 1).   
Congenital diarrheal disorders are a heterogeneous group of inherited diseases of 
the digestive system and are frequently life-threatening if untreated2,3,4 (see Suppl. Text 
for additional clinical background).  We studied eight patients from seven unrelated 
families of common ethnogeographic origin with an autosomal recessive pattern of severe 
congenital malabsorptive diarrhea named IDIS (for Intractable Diarrhea of Infancy 
Syndrome)4 (Fig. 1a,b; Extended Data Fig. 1; Suppl. Text).  Initial WES analysis 
revealed no rare exonic sequence variants with the appropriate patient segregation.  
However, whole genome linkage analysis and haplotype reconstruction detected a single 
 
 
significant telomeric linkage interval on chromosome 16 (LOD = 4.26; Extended Data 
Fig. 2, see Suppl. Text).  We examined WES and WGS data from selected patients and 
observed a 7,013 bp deletion, termed ΔL, in the absence of other structural changes or 
coding mutations at the affected locus (Fig. 1c, Extended Data Fig. 1 and 3, Suppl. Text).  
Two of the patients (4.1 and 4.2) were compound heterozygous for ΔL, along with a second 
variant, termed ΔS, which contains a 3,101 bp deletion that partially overlaps ΔL, defining 
a minimal sequence termed intestine-critical region (ICR) of 1,528 bp (Fig. 1c).  All eight 
patients in this study showed ICRΔS/ΔS, ICRΔS/ΔL or ICRΔL/ΔL genotypes, resulting in a 
homozygous deletion of the ICR that was not detected in any of the control groups 
examined (Extended Data Fig. 1, Suppl. Text).  These data suggest that the deletion of 
the ICR causes the congenital diarrhea phenotype. 
To explore possible noncoding functions of the ICR, we examined Encyclopedia of 
DNA Elements (ENCODE) data5.  The ICR contains a 400 bp region with high 
evolutionary conservation across vertebrates, includes CpG island and DNase 
hypersensitivity signatures, and encompasses a cluster of multiple binding sites for 
transcription factors including FOXA1 and FOXA26,7 (Fig. 1c).  To test the hypothesis that 
the ICR contains a regulatory sequence, we examined its in vivo activity in a transgenic 
mouse reporter assay8.  In transgenic embryos ranging from embryonic day (E) 11.5 to 
E14.5, we observed robust and reproducible reporter activity in the stomach, pancreas, and 
duodenum (Fig. 2a,b).  These results support the notion that the ICR lost in congenital 
diarrhea patients contains a gene regulatory sequence that is active in the developing 
digestive system.   
To examine if loss of the ICR sequence is sufficient to cause the phenotypes 
observed in human patients, we deleted a 1,512 bp interval from the mouse genome that 
included the mouse orthologues of the human DNase hypersensitivity signature and 
predicted FOXA1/2 binding sites (Fig. 1d, Extended Data Fig. 4).  Homozygous 
chr17ΔICR/ΔICR pups were born at the expected Mendelian frequency and showed no gross 
phenotypes at birth.  However, starting within the first few days of life, chr17ΔICR/ΔICR mice 
displayed overall reduced size (Figs. 1e, 2c), low body weight (Fig. 2d), and substantially 
decreased survival (Fig. 2e).  Examination of fecal pellets and internal organs revealed 
abnormal digestive tract function in chr17ΔICR/ΔICR mice (Fig. 1f; Extended Data Fig. 5), 
 
 
as well as changes in the composition of the intestinal microbiome in chr17ΔICR/ΔICR mice 
(Extended Data Fig. 6; Suppl. Text).  Our combined results indicate that deletion of the 
ICR in mice causes disruption of intestinal function, recapitulating the congenital diarrhea 
phenotype observed in human patients carrying homozygous ICR deletions. 
Next, we sought to elucidate the molecular mechanisms through which deletion of 
the ICR causes deficiencies in gastrointestinal function.  Targeted expression analysis of 
stomach and intestinal mouse tissue samples covering developmental stages ranging from 
E14.5 to P20 revealed an unannotated region flanking the ICR that showed very low levels 
of expression in wildtype prenatal stomach tissue (Fig. 3a).  Expression of this sequence 
was completely lost in matched tissues from chr17ΔICR/ΔICR littermates, suggesting the 
presence of a gene previously unannotated in both the human and mouse genomes 
(Extended Data Fig. 4c).  Sequence analysis identified an 897-bp open reading frame 
predicted to encode a protein that is Proline and glutamate (E) Rich and contains an N-
terminal Coiled Coil domain (PERCC1, Fig. 3b).  Despite overall strong evolutionary 
conservation across vertebrates (Fig. 3c), PERCC1 homology- and structure- based 
searches failed to identify similarities to known proteins.  However, comparison of human 
and mouse non-synonymous and synonymous substitutions showed a dN/dS ratio of 0.17, 
further supporting that PERCC1 represents a bona fide protein-coding gene (Fig. 3d).  
To compare the spatiotemporal expression of mouse Percc1 with the regulatory in 
vivo activity of the ICR, we performed mRNA in situ hybridization for Percc1.  At E14.5, 
we observed a pattern of punctate Percc1 expression in stomach, pancreas, and intestine 
highly reminiscent of ICR activity (Extended Data Fig. 7, Fig. 2a,b).  To further establish 
a functional connection between the ICR regulatory sequence and the predicted open 
reading frame, we used genome editing to disrupt the Percc1 open reading frame in mice.  
Percc1-/- mice mimicked the key phenotypes of chr17ΔICR/ΔICR mice, including low body 
weight (Extended Data Fig. 8) and abnormal appearance of intestinal content (n=11/12 
[92%] in Percc1-/-; n=20/21 [95%] in chr17ΔICR/ΔICR; p=0.7, two-tailed T-test). Finally, to 
establish that Percc1 expression is sufficient to rescue the phenotypes resulting from 
deletion of the ICR regulatory sequence, we performed a complementation experiment in 
which we generated chr17ΔICR/ΔICR mice with an ICR-Percc1 transgene.  Upon 
complementation, we observed reversal of the reduced body weight, high lethality, and 
 
 
intestinal dysfunction found in chr17ΔICR/ΔICR mice (Extended Data Fig. 9).   These results 
establish that lack of gastrointestinal expression of PERCC1, normally controlled by the 
ICR, causes the phenotypes observed in chr17ΔICR/ΔICR mice and likely in IDIS patients 
examined in this study. 
To explore the cell type specificity and function of PERCC1, we generated a 
transgenic mouse line encoding a PERCC1-mCherry fusion protein (Fig. 4a, Extended 
Data Fig. 10, 11).  At postnatal day 8, some PERCC1-mCherry positive (PERCC1+) cells 
were detected in the epithelium of the intestinal villi (Extended Data Fig. 11b), whereas 
distal stomach compartments displayed a high density of strongly positive cells, in 
particular in the epithelial layers of the pylorus, antrum, and corpus (Fig. 4a, Extended 
Data Fig 11a). Co-localization with the pan-endocrine marker Synaptophysin (SYP) 
revealed that a major fraction of PERCC1-positive cells in these compartments are 
endocrine cells (Fig. 4a, Extended Data Fig. 11b).  The vast majority of PERCC1+ cells 
detected in the antral epithelium were Gastrin-expressing G-cells (Fig. 4a), which are 
required for secretion of gastric acid and promote growth of the gastrointestinal tract9 .  In 
contrast, the glandular epithelium at the entrance to the pyloric canal also contained clusters 
of PERCC1+ cells without endocrine signatures located at the gland base, a region known 
to harbor gastric stem cells10 (Fig. 4a). As the majority of PERCC1+ cells in the distal 
stomach were G-cells, we next investigated whether loss of Percc1 in mice affected the 
development of these cells. We observed that the number of Gastrin-expressing cells was 
reduced in the absence of Percc1 (Extended Data Fig. 11c).  Finally, analysis of 11,665 
single cell transcriptomes from mouse intestinal epithelium11 showed that Percc1 is 
expressed in a small proportion of cells that are strongly enriched for enteroendocrine cells 
(EECs; p = 2.9e-20, chi-squared test, Extended Data Fig. 12a). Percc1-positive cells 
express Sox4 and Neurog3, and their expression profiles are most consistent with an 
enteroendocrine progenitor identity (Extended Data Fig. 12b, c).  These data indicate that 
expression of PERCC1 in gastrointestinal tissue is restricted primarily to gastric G-cells 
and duodenal enteroendocrine cells, and suggest that disrupted development of these cells 
causes the observed phenotype.  
To characterize the molecular consequences of loss of the ICR or Percc1 in more 
detail, we examined RNA-seq data from relevant stages of mouse development.  Among 
 
 
the 100 genes showing the greatest reduction in expression, seven encode gastrointestinal 
peptide hormones secreted by EECs12 (Figure 4b, Table 1, Suppl. Table S1).  Strikingly, 
reduction of Gastrin expression (Gast) appears as one of the most robust changes, along 
with changes in Somatostatin (Sst) and Ghrelin (Ghrl) expression (Figure 4d, e).  We 
observed similar gene expression changes in duodenal and stomach biopsies obtained from 
an ICRΔL/ΔL patient and an unaffected ICR+/+ sibling (Table 1; Suppl. Table S2; Extended 
Data Fig. 13).  Together, these results are consistent with major disruptions of normal 
gastrointestinal physiology in chr17ΔICR/ΔICR mice and human IDIS patients and highlight 
the close resemblance between the human disease condition and our mouse knockout 
models. 
 We also generated induced pluripotent stem cells (iPSC) from an ICRΔL/ΔL patient 
and an unaffected ICR+/+ sibling and differentiated them into human intestinal organoids 
(HIOs) (Extended Data Fig. 14/15)13.  The gross morphology of ICRΔL/ΔL and control 
ICR+/+ HIOs was overall similar and at early stages (21 days) the ICRΔL/ΔL HIOs revealed 
an abundant presence of EECs (Extended Data Fig. 11d).  In contrast, by day 42 the 
ICRΔL/ΔL HIOs showed a severe reduction in the number of EECs compared to control 
HIOs, along with reduced expression of EEC markers Chromogranin A (CHGA) and 
Synaptophysin (SYP) (Fig. 4c; Extended Data Fig. 11d).  These results suggest that 
disruption of the ICR is compatible with the initial formation of EECs, but interferes with 
their subsequent development.  
Limited understanding of the in vivo function of human protein-coding genes and 
noncoding sequences continues to be a grand challenge preventing the systematic 
interpretation of disease-related data from WES and WGS studies.  In the present work we 
establish that IDIS, a severe, recessively inherited gastrointestinal disease, is caused by 
microdeletions that disrupt a regulatory sequence required for normal intestinal expression 
of the previously unannotated PERCC1 gene.  The molecular, cellular, and physiological 
phenotypes observed in human patients and engineered mice indicate that PERCC1 is 
required for normal development of EECs and, thereby, normal enteroendocrine hormone 
secretion.  The phenotype of chr17ΔICR/ΔICR mice resembles that of mice with an intestinal-
specific deletion of Neurog3, a proendocrine transcription factor required for development 
of EECs14, further supporting abnormal EEC development as the cause of IDIS.  The 
 
 
different etiologies of chronic diarrhea of infancy and enteropathies have recently been 
reviewed and classified into distinct categories15. Among these categories, disorders of 
enteroendocrine cell function, caused by mutations in Neurog3, Arx, Pcsk1, Rfx6, are 
described as a unique and separate entity that manifest with malabsorptive diarrhea.  The 
phenotypes observed in human patients and engineered mice indicate that IDIS is most 
similar to this specific class of chronic diarrheal disorders.  Beyond congenital diarrhea, 
our results serve as a reminder that, despite extensive annotation efforts, protein-coding 
genes associated with disease phenotypes remain to be discovered.  As WGS is 
increasingly used for studies of rare diseases, our work underscores the importance of 
detailed experimental follow-up of such findings through in vivo models.    
 
 
 
Figure Legends 
Figure 1. Overview of human and mouse locus and key findings. a/b, Selected family 
pedigrees and genotyping results for patients compound heterozygous for the two deletion 
alleles (a) and homozygous for one of the deletion alleles (b).  c/d, Genomic map of the 
deletion alleles in human (c; genome build GRCh37) and mouse (d), indicating the location 
of ΔL and ΔS, as well as their minimal overlapping region ICR. Exome sequencing data is 
capped at up to 5 overlapping tags for visualization; vertebrate conservation is 100-
vertebrate PhyloP; only selected transcription factor binding sites and DNase 
hypersensitivity clusters with signal in >20/125 ENCODE cell types shown.  e, General 
appearance of wildtype (n=50) and chr17ΔICR/ΔICR (n=46) mice at 21 days after birth, 
showing overall significantly reduced size (see Fig 2d).  g, Abnormal appearance of fecal 
pellets from chr17ΔICR/ΔICR mice (n=46).  
 
Figure 2.  Enhancer activity of the ICR and mouse deletion phenotypes. a-b, Enhancer 
reporter activity in transgenic mouse embryos.  a, Mouse embryo cross-sections showing 
X-gal staining for b-galactosidase activity in E13.5 stomach, pancreas and duodenum as 
marked.  b, E14.5 cross-section showing immunofluorescence with anti-b-galactosidase 
(ICR activity, red), anti-endomucin (endothelial cells, green), and DAPI (DNA, blue).  a/b, 
Two embryos for each experiment and each condition were collected and a minimum 
of three sections from each embryo were examined.  Representative sections are shown. c, 
Chr17ΔICR/ΔICR mice (n=46) are viable but show a reduction in size and weight compared 
to wild-type littermates (n=50).  d/e, Reduction in body weight among surviving offspring 
(d) and increased mortality (e) of chr17ΔICR/ΔICR compared to wild-type.  Body weight of 
female mice shown in (d); male wildtype and chr17ΔICR/ΔICR mice had similar genotype-
dependent weight differences. 
 
Figure 3.  Discovery of a novel gene, Percc1, flanking the ICR.  a, Gene expression 
levels of Percc1 in gastrointestinal tissues from wildtype (wt) and chr17ΔICR/ΔICR mice.  
 
 
Highest levels of expression were detected in stomach at postnatal day 10 (P10).  b, Mouse 
genome view of Percc1 gene localization and structure.  Stranded RNA-seq data indicating 
expression loss of Percc1 in knockout mice compared to controls (bottom panel).  c, 
Detailed view of the Percc1 gene and evolutionary conservation.  d, Percc1 codon position 
analysis illustrating the relaxation of constraint in the third codon position of the predicted 
Percc1 protein (n = 274).  dN/dS ratio and corresponding P-value calculated using 
Phylogenetic Analysis using Maximum Likelihood (Chi-square distribution). 
 
Figure 4: PERCC1 is abundant in G-cells and its genetic disruption impairs 
gastrointestinal peptide hormone expression and enteroendocrine cell development. 
a, Top: Generation of a reporter fusion transgene to track PERCC1 localization in murine 
gastrointestinal tissues. The genomic sequence spanning the ICR and Percc1 ORF were 
fused to mCherry. Lower left panels: PERCC1+ cells (red) in the pyloric antrum at 
postnatal day 8 (P8) show endocrine identity marked by Synaptophysin (Syp, green) and 
extensive overlap with the endocrine subset of Gastrin-expressing G-cells (blue). 
Arrowheads indicate triple-positive cells. Nuclei are shown in gray. Lower right panels: 
PERCC1+ cells in the pyloric canal carry either endocrine G-cell identity (arrowheads) or 
appear frequently clustered at the gland base (arrows). n represents independent biological 
replicates with similar results. Scale bars, 50µm. b, RNA-seq from mouse stomach samples 
across different timepoints (n = 1 biological replicates) reveals reduced transcript levels of 
different gastric peptide hormones in DICR/DICR mice. Sst, Somatostatin; Gast, Gastrin; 
Grhl, Ghrelin; Pyy, Peptide YY; Gcg, Glucagon; Fndc5, Fibronectin type III domain-
containing protein 5; Adipoq, Adiponectin precursor. c, Quantitative RT-PCR analysis of 
induced pluripotent stem cell (iPS)-derived human intestinal organoids (HIOs) from 
patients with disrupted PERCC1 (ΔL/ΔL) vs. control siblings. In contrast to Chromogranin 
A (CHGA), Synaptophysin (SYP) is significantly downregulated in patient-derived HIOs 
(p<0.05) (two-tailed, unpaired t-test). iPS, induced pluripotent stem cells. Box plot 
indicates median, interquartile values, range, outliers (circled dots) and individual technical 
replicates (from independent organoid preparations).  
 
 
 
 
 
Methods 
Experimental Design 
All animal work was reviewed and approved by the Lawrence Berkeley National 
Laboratory Animal Welfare Committee. All mice used in this study were housed at the 
Animal Care Facility (the ACF) at LBNL. Mice were monitored daily for food and water 
intake, and animals were inspected weekly by the Chair of the Animal Welfare and 
Research Committee and the head of the animal facility in consultation with the veterinary 
staff. The LBNL ACF is accredited by the American Association for the Accreditation of 
Laboratory Animal Care (AAALAC). Generation of transgenic mice and manipulation of 
genomic sequence were performed in Mus musculus FVB strain mice, mice with 
C57/129S6 mixed background or W4/129S6 ES cells (see below for details). Animals of 
both sexes were used in the analysis. Sample size selection and randomization strategies 
were conducted as follows:  
Transgenic mouse assays. Sample sizes were selected empirically based on our previous 
experience of performing transgenic mouse assays for >2,000 total putative enhancers 
(VISTA Enhancer Browser: https://enhancer.lbl.gov/). Mouse embryos or postnatal mice 
were excluded from further analysis if they did not contain the reporter transgene or if the 
stage was not correct. All transgenic mice were treated with identical experimental 
conditions. Randomization and experimenter blinding were unnecessary and not 
performed. 
Genomic knockouts. Sample sizes were selected empirically based on our previous 
studies16. All phenotypic characterization of knockout mice employed a matched littermate 
selection strategy. All phenotyped homozygous knockout mice described in the paper 
resulted from crossing heterozygous knockout mice together to allow for the comparison 
of matched littermates of different genotypes. Embryonic samples used for RNA-seq and 
immunofluorescence were dissected blind to genotype. RNA-seq libraries were prepared 
and sequenced in mixed batches (including both KO and WT samples). 
 
 
Subjects: IDIS patients were recruited at Schneider and Sheba medical centers in Israel. 
Clinical details of the subjects are provided in Supp. Table S4. All procedures performed 
in this study involving human participants were in accordance with the ethical standards of 
the institutional research committee and with the 1964 Helsinki Declaration and its later 
amendments or comparable ethical standards. Informed consent was obtained from all 
individual participants and/or their legal guardian involved in the study. 
Exome sequencing and variants identification: Exome sequencing was performed using 
Agilent SureSelect Human All Exon technology (Agilent Technologies, Santa Clara, CA). 
The captured regions were sequenced using Genome Analyzer IIx (Illumina, Inc. San 
Diego, CA). The resulting reads were aligned to the reference genome (build 37) using the 
Burrows-Wheeler Alignment (BWA) tool17. We obtained 70´ coverage, where a base was 
considered covered if ≥5 reads spanned the nucleotide. Genetic differences relative to the 
reference genome were identified by the SAMtools v0.1.7a variant calling program18, 
which identifies both single nucleotide variants and small insertion-deletions (indels). 
Finally, the Sequence Variant Analyzer software (SVA v1.10)19 was used to annotate all 
identified variants. For comparison to controls, we utilized 1000 samples subjected to 
exome or whole genome sequencing at the Center for Human Genome Variation (CHGV, 
Duke University, NC, USA), dbSNP, 1000 genomes, and NHLBI GO Exome-sequencing 
Project.  
Whole genome sequencing: WGS of individual 2.1 was performed at CHGV, using the 
Illumina HiSeq platform (Illumina, Inc. San Diego, CA) and analyzed as described for 
exome data. 275 CHGV whole-genome sequenced, unrelated samples were used as 
controls. To detect copy number variants from WGS we used the estimation by read depth 
with single-nucleotide variants (ERDS) tool20. 
Biopsy collection: Subjects underwent gastro-duodenoscopy following Institutional 
Review Board (IRB) approval (No. 9881-12-SMC) at Sheba Medical Center and written 
informed consent of the patients and family members.  
RNA extraction from biopsies: RNA isolation from frozen biopsies was performed using 
TRI Reagent method (Sigma-Aldrich Inc.) according to the manufacturer’s instructions or 
by Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA, USA).  Integrity of the samples was 
 
 
measured for concentration and purity using a NanoDrop Spectrophotometer (Nanodrop 
Technologies, Wilmington, DE, USA). 
RNA sequencing of human samples: Total RNA was prepared according to the Illumina 
RNA-seq protocol. Briefly, globin reduction, polyA enrichment, chemical fragmentation 
of the polyA RNA, cDNA synthesis, and size selection of 200bp cDNA fragments were 
performed. Next, the size-selected libraries were used for cluster generation on the flow 
cell and prepared flow cells were run on the Illumina HiSeq2000 (Illumina, Inc. San Diego, 
CA). We obtained a total of 74.18 million paired-end reads of 100 bp for the affected 
sample and 72.53 million reads to the healthy sample. Reads were align to the human 
genome (NCBI37/hg19) using Tophat v2.0.421 with the default parameters. Gene 
expression quantification was performed with Cuffdiff v2.0.221 using the Illumina 
iGenome project UCSC annotation file as a reference. Differentially expressed genes were 
defined using the following thresholds: 1.5 fold change, p-value ≤ 0.05. 
Quantitative Real-Time Reverse Transcriptase (RT) Polymerase Chain Reaction 
(qPCR): RNA extracted from biopsies was used for RT-PCR expression analyses. RT-
PCR were performed using TaqMan Gene Expression Assays (Applied Biosystems, Foster 
City, CA, USA) using the Applied Biosystems StepOnePlus (Applied Biosystems). From 
1 µg of biopsy RNA, cDNA was synthesized using the SuperScript® First-strand Synthesis 
System for RT-PCR (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's 
instructions. A total of 20µl of cDNA was added with 30µl of water to 50µl of TaqMan 
universal PCR Master Mix (Applied Biosystems) and the resulting 100µl reaction mixtures 
were loaded onto a 96-well PCR plate. We used 14 different TaqMan Gene Expression 
Assays including three housekeeping genes with the following assays IDs: 
Hs00757713_m1 (MLN), Hs01074053_m1 (GHRL), Hs00175048_m1 (NTS), 
Hs00356144_m1 (SST), Hs00174945_m1 (PYY), Hs01062283_m1 (GAST), 
Hs00292465_m1 (ARX), Hs00174937_m1 (CCK), Hs00175030_m1 (GIP), 
Hs00219734_m1 (GKN1), and Hs00699389_m1 (GKN2). The housekeeping genes we 
used were HMBS (Hs00609297_m1), ACTB (Hs99999903_m1) and GAPDH 
(Hs99999905_m1). Reference cDNA samples were synthesized using 200 ng of RNA from 
RNA extracted from stomach and duodenum tissues of two healthy controls (BioCat 
GmbH, Heidelberg, Germany) for use in the normalization calculations. qPCR for 
 
 
expression analysis on the missing exons in C16ORF91 was done using cDNA extracted 
from the Human Digestive System MTC Panel (Clontech Laboratories, Inc. Mountain 
View, CA).  
Serum Collection: Whole blood was withdrawn into a Vacutainer serum tube without anti-
coagulant. The blood was immediately treated with 1µM AEBSF (protease inhibitor) and 
remained at room temparature for 30 min to clot before centrifugation (15 min at 2500 rpm 
at 4°C).   
ELISA: Serum hormone levels were determined using the sandwich ELISA technique 
performed by the following commercial kits according to the manufacturer’s instructions. 
Human Ghrelin (Total) ELISA COLD PACKS (Millipore, USA), Human PYY (Total) 
ELISA Kit (Millipore), and Human gastric inhibitory polypeptide (GIP) ELISA Kit 
(ENCO).      
Linkage analysis and homozygosity mapping: Genome-wide SNP genotyping from 
DNA of 6 affected children and 22 relatives from families 1-5 was performed using the 
Illumina HumanCytoSNP-12v2-1_H, according to the manufacturer’s recommendations 
(Illumina, Inc. San Diego, CA) in conjunction with SNP genotypes retrieved from whole 
exome data. For linkage studies 35,845 informative equally spaced SNP markers were 
chosen after filtering for Mendelian errors and unlikely genotypes. Genotypes were 
examined with the use of a multipoint parametric linkage analysis and haplotype 
reconstruction for an autosomal recessive model with complete penetrance and a disease 
allele frequency of 0.001 as previously described22. Homozygosity mapping was 
performed using PLINK v1.0723 with the default parameters (length 1000 kb, SNP(N) 100, 
SNP density 50 kb/SNP, largest gap 1000 kb). 
Deletion analysis: Boundaries for the two deletion alleles were determined by PCR using 
amplified DNA and Sanger sequencing. The specific primers used to amplify across both 
deletions and inside the overlapping region for the two deletions are reported in Supp. 
Table S5. In parallel, we used polymorphic markers that were identified by electronically 
screening genomic clones located on Chr16 0.86-2.8Mb. Primers were designed with the 
Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi/ from the 
Whitehead Institute, Massachusetts Institute of Technology, and Cambridge, MA). The 
 
 
specific primers used are reported in Supp. Table S6.  Amplification of the polymorphic 
markers was performed in a 25µl reaction containing 50 ng of DNA, 13.4 ng of each 
primer, and 1.5 mM dNTPs in1.5 mM MgCl2 PCR buffer with 1.2 U Taq polymerase (Bio-
Line, London, UK). After an initial denaturation of 5 min at 95°C, 30 cycles were 
performed (94°C for 2 min, 56°C for 3 min, and 72°C for 1 min), followed by a final step 
of 7 min at 72°C. PCR products were electrophoretically separated on an automated genetic 
analyzer (Prism 3100; Applied Biosystems, Inc. [ABI], Foster City, CA). The breakpoints 
coordinates were : ∆L- chr16: 1475365-1482378, ∆S- chr16:1480850-1483951, with an 
overlapping region at chr16: 1480850-1482378 (ICR).  
Mouse transgenic assays: The candidate gene regulatory sequence (chr 16: 1479875 – 
1480992) was PCR amplified from human genomic DNA and was cloned into the hsp68-
lacZ transgenic vector containing a minimal hsp68 promoter coupled to a lacZ reporter 
gene.  The purified transgene construct was microinjected into fertilized FVB/N mouse 
oocytes, which were implanted into pseudopregnant foster females and embryos were 
collected at E11.5 through E14.5.  Transgenic activity was determined by X-gal staining 
to detect b-galactosidase activity. Only patterns observed in at least three different embryos 
resulting from independent transgenic events were considered reproducible positive 
enhancers.  All animal work was reviewed and approved by the Lawrence Berkeley 
National Laboratory Animal Welfare and Research Committee.   
Generation of ICR knockout mice (chr17ΔICR/ΔICR):  Homologous arms were generated 
by PCR (see Suppl. Table S7 for primers) and cloned into the ploxPN2T vector, which 
contains a neomycin (G418)-resistant cassette flanked by loxP sites for positive selection, 
and an HSV-tk cassette for negative selection. Constructs were linearized and 
electroporated (20µg) into W4/129S6 mouse embryonic stem cells (Taconic).  The 
electroporated cells were selected under G418 (150µg/ml) and 0.2µM FIAU for a week.  
Surviving colonies were picked and expanded on 96-well plates, screened by PCR and 
sequencing with primers outside but flanking the homology arm.  Clones that were 
correctly targeted were electroporated with 20µg of the Cre recombinase-expressing 
plasmid TURBO-Cre.  TURBO-Cre was provided by Dr. Timothy Ley of the Embryonic 
Stem Cell Core of the Siteman Cancer Center, Washington University Medical School.  
 
 
Clones positive for Neo removal were screened by PCR and checked for G418 sensitivity. 
PCR products covering the deleted region and part of homologous arms were gel purified 
and sequenced to confirm the deletion of the ICR.  Correctly targeted clones were 
subsequently injected into C57BL/6J blastocyst stage embryos. Chimeric mice were then 
crossed to C57BL/6J mice (Charles River) as well as 129S6/SvEvTac (Taconic) to generate 
heterozygous ICR-null mice, followed by breeding of heterozygous littermates to generate 
homozygous null mice. 
Genotyping of chr17ΔICR mice: Genomic DNA was extracted from a 0.2 to 0.3-cm section 
of tail that was incubated overnight in lysis buffer (containing 100mM Tris-HCl pH 8.5, 
5mM EDTA, 0.2% SDS, 200mM NaCl and 50µg Proteinase K) at 55°C. Genotyping was 
carried out using standard PCR techniques (see Suppl. Table S7 for primers). 1-2µl of 50- 
to 100-fold diluted tail lysate was used in a 20µl PCR containing 200 µM dNTP, 1.5 mM 
MgCl2, 5 pmole of each forward and reverse primer and 0.5U of Taq polymerase. 
RNA sequencing of mouse tissues: Total RNA was extracted from different intestinal 
regions and stomach of mice at E11.5, P1, P5, P10, P15 and P20 using TRIzol Reagent 
(Invitrogen). RNAseq libraries were then constructed using Illumina TruSeq Stranded 
Total RNA Sample Preparation Kit following manufacturer’s recommendation.  The 
libraries were sequenced using a 50bp single end strategy with four samples per lane on an 
Illumina HiSeq instrument, and data were analyzed using the same protocols as described 
for human, though with the mm9 mouse reference and Illumina iGenome project mouse 
genome annotation data.  The RNA-seq data can be accessed under GEO number 
GSE94245. DAVID v6.724 was run separately on the differentially expressed genes in the 
P10 stomach (167 down-regulated, 187 up-regulated, Supp. Table S1) or in the P10 
intestine (326 down-regulated, 327 up-regulated, Supp. Table S1). The resulting lists of 
clustered terms were inspected for highly significant enrichment (q-value ≤0.05) for 
biological process (GO), molecular function (MF), or pathway (KEGG) (see Supp. Table 
S3). The most significant term for each cluster was retained. In total, 59 genes showing 
any of these annotations were also found in the top 100 deregulated genes (either up- or 
down- regulated, separately for each tissue). A selection of genes from these 59 is 
highlighted in Table 1. 
 
 
16S amplicon analysis (iTags) of microbial community diversity:  Feces and gut content 
samples were collected from chr17ΔICR/ΔICR mice and wild type littermates. DNA was 
extracted from these samples using PowerFecal DNA Isolation Kit (MO Bio Laboratories). 
V4 16S regions were amplified from the DNA samples using barcoded primers and 5 
PRIME™ HotMasterMix (Fisher Scientific) as previously described25. Amplicons were 
pooled in equal amount, purified with AMPureXP magnetic beads (Beckman Coulter), and 
sequenced. 
Percc1 RT-PCR, RT-qPCR and 5’, 3’-RACE:  Total RNA was extracted from intestine 
and stomach of mice using TRIzol Reagent (ThermoFisher Scientific) and total RNA was 
DNase (Promega) treated.  First strand cDNA was generated from the DNase-treated total 
RNA using SuperScript First-Strand Synthesis System (ThermoFisher Scientific).  RT-
qPCR was performed using KAPA SYBR FAST Roche LightCycler 480 2X qPCR Master 
Mix (KAPA Biosystems).  To identify the expression boundaries of the Percc1 
transcript(s), regular RT-PCR, 5’-RACE and 3’-RACE were performed (primers used can 
be found in Supp. Table S8).  Standard RT-PCR used Platinum Taq DNA Polymerase 
High fidelity (ThermoFisher Scientific) while 5’- and 3’- RACE used the SMARTer RACE 
5’/3’ Kit (Clontech). PCR products were gel purified and Sanger sequenced.  The cDNA 
and predicted protein sequence are available in Genbank record KY964488.  It should be 
noted that since our original identification of Percc1, the Havana gene annotation project 
manually curated this open reading frame as uncharacterized LOC105371045. 
Percc1 knockout mice by CRISPR/Cas9:  Percc1 knockout mice were generated by 
CRISPR/Cas9 editing as previously described26,27.  Single guide RNAs (sgRNAs) were 
constructed using 60-mer oligonucleotides and an sgRNA cloning vector (Addgene 
plasmid 41824)28 according to the following protocol: 
http://www.addgene.org/static/cms/files/hCRISPR_gRNA_Synthesis.pdf.  The sgRNA 
target site sequences are provided in Supp. Table S9.  Cas9 mRNA was generated using a 
human codon-optimized Cas9 gene from plasmid pDD92129. T7-promoter-Cas9-polyA 
and T7-promoter-sgRNA amplicons were PCR amplified from pDD921 and sgRNA 
clones, respectively, using Phusion polymerase (New England Biolabs).  Cas9 RNA was 
generated by in vitro transcription from the T7promoter-Cas9-polyA amplicon using 
mMESSAGE mMACHINE T7 Kit (ThermoFisher Scientific), following the 
 
 
manufacturer’s instructions.  sgRNA RNA was generated by in vitro transcription from the 
T7-promoter-sgRNA amplicon using MEGAshortscript Kit (ThermoFisher Scientific), 
following manufacturer’s instructions. In vitro-transcribed RNA was cleaned using 
MEGAclear Kit (ThermoFisher Scientific), following the manufacturer’s instructions. 
RNA was eluted into RNase-free microinjection buffer (10 mM Tris, pH7.5; 0.1 mM 
EDTA). The RNA was then assessed by electrophoresis on a 10% TBE Urea PAGE gel. 
Microinjection and generation of genetically modified mice: A mixture of 100 ng/µl 
Cas9 RNA and 50 ng/µl total sgRNA RNAs in microinjection buffer was injected into 
cytoplasm of fertilized mouse strain FVB/N mouse oocytes.  Pups generated (F0) were 
screened by PCR (primers listed in Supp. Table S9) and resulting PCR products were 
sequenced to identify deletion breakpoints.  
Complementation of chr17ΔICR/ΔICR with a Percc1 mouse transgene: An 8530bp region 
was PCR-amplified from W4/129S6 mouse genomic DNA (primer sequences can be found 
in Suppl. Table S10). The region amplified includes all putative Percc1 exons, a possible 
promoter, and the 3’-UTR. The resulting PCR product was cloned into pCR2.1 vector 
(Invitrogen TOPO® TA Cloning® Kit) and verified by sequencing. To generate transgenic 
mice, a purified, linear transgene fragment was injected into the pronucleus of fertilized 
eggs from chr17ΔICR/+ intercrosses. Offspring were PCR genotyped for existence of the 
Percc1 transgene and examined for phenotypes found in chr17ΔICR/ΔICR mice. 
Generation of PERCC1-mCherry fusion protein transgenic mice: A 3308bp fragment 
covering the Percc1 promoter to the last amino acid of the Percc1 coding region was PCR 
amplified and cloned into the pcDNA3 mCherry LIC cloning vector 6B (Addgene, 
#30125) 5’ of the mCherry cDNA to generate a mouse Percc1-mCherry fusion construct 
(primers can be found in Suppl. Table S11). The construct was linearized with NotI and 
injected into the pronucleus of fertilized FVB eggs to generate transgenic mice. 
Western blotting: Tissues (stomach and intestine) were lysed and homogenized in T-
PER™ Tissue Protein Extraction Reagent (ThermoFisher Scientific, #78510) plus Protease 
Inhibitor (Sigma, #P8340). Protein concentration was determined using Pierce™ 
Coomassie (Bradford) Protein Assay Kit (ThermoFisher #23200).  100µg of lysate per well 
of each sample was loaded on Bolt™ 4-12% Bis-Tris Plus Gel (ThermoFisher, 
 
 
#NW04120BOX), along with SeeBlue® Plus2 Pre-Stained Standard (ThermoFisher 
Scientific, LC5925) and 0.1 µg mCherry protein (VWR #10190-818) as a positive control. 
After electrophoresis at 200V for 35 minutes, the gel was blotted on 0.45 µm pore size 
PVDF membrane using XCell II™ Blot Module (ThermoFisher Scientific). The membrane 
was then blocked with 3% nonfat milk in TBS (Sigma, T8793). Primary antibody, mCherry 
Antibody (ThermoFisher Scientific, #PA5-34974), was added to the blot at 1:1000 dilution 
in 3% nonfat milk in TBS, and incubated overnight at 4 °C. Following several washes with 
TBST (Sigma, T9039-10PAK), HRP-conjugated goat anti-rabbit antibody (ThermoFisher 
#31460) was added at 1:3000 dilution in TBST and incubated at room temperature for 1 h. 
mCherry protein was detected with 1-Step Ultra TMB-Blotting Solution (ThermoFisher 
Scientific, #37574). 
Tissue embedding and cryosectioning:  The stomach was dissected out from Percc1-
mCherry transgenic mice at age of P8 and fixed in 4% PFA for 2-3 hours at 4 °C. After 
several washes with PBS, the tissue was soaked in 10%, 20% and 30% sucrose in PBS, 
each for 1 h at 4°C and then embedded in a 1:1 mixture of Tissue-Tek O.C.T. Compound 
(VWR, #25608-930) and 30% sucrose in PBS. Embedded tissue was sectioned using a 
cryostat (10µm sections). 
Immunofluorescence and cell counting:  Cryosections were washed with PBS 3´ for 5 
min each wash, incubated in 0.2% TritonX-100 in PBS for 20 min and washed again with 
3´ in PBS for 5 min each wash at room temperature. Sections were blocked with 1% BSA 
in 0.1% PBT for 1 h at room temperature. Primary antibodies against mCherry (1:500, 
ThermoFisher Scientific, #PA5-34974), Synaptophysin (1:1000, Synaptic Systems, cat# 
101004), Gastrin (1:500, C-20, Santa Cruz Biotechnology, #sc-7783), anti-E-Cadherin 
(1:500, BD Biosciences, cat# 610181), beta-galactosidase (1:500, Abcam, #ab9361) and  
Endomucin (1:500, eBiosciences #14-5851-82) were used and incubated overnight at 4°C. 
After washing sections with 3´ with PBS for 5 min each wash, sections were incubated for 
1h at room temperature with combinations of Alexa Fluor 488 and 594 (for double 
fluorescence) or Alexa Fluor 488, 568 and 647 (for triple fluorescence) conjugate 
secondary antibodies (ThermoFisher Scientific) each at a 1:1000 dilution in 1% BSA in 
PBS. Sections were then washed 2´ with PBS, treated with Hoechst for counterstaining of 
 
 
nuclei and mounted in Mowiol or VECTASHIELD HardFSet Mounting Medium (Vector 
Laboratories, #H-1500).  Gastrin-positive cells were counted on consecutive stomach 
sections of wild-type (N=3) and ICR knockout (N=2) mice at P8. The fraction of gastrin-
expressing cells was calculated by normalization to the total number of nuclei determined 
via Cell Profiler (http://cellprofiler.org). Cell counts from each antral side (as shown in the 
schematic of Extended Data Figure 11c) were averaged. 
Mouse Intestine Single Cell Analysis:  Single-cell RNA-seq profiles11 were retrieved 
from the Gene Expression Omnibus30 (GEO, GSE92332). SAM alignment files18 were 
downloaded from the Short Read Archive using the sam-dump utility (part of the SRA 
Toolkit v2.8.1, http://ncbi.github.io/sra-tools/). Coordinates of the reads mapping to 
Percc1 were extracted using SAMtools v1.3.118, along with the corresponding cell 
barcodes and UMIs (CB:Z and UB:Z, respectively). These allowed the assignment of each 
unique transcript (via UMI) to the parental cell (via cell barcode). Cell-type classification 
as described in Haber et al11. were parsed from GSE92332_Regional_UMIcounts.txt.gz 
(available on the GEO, GSE92332).  All the further data processing steps, plots and p-
values calculations were performed in the statistical computing environment R v.3.4.2 
(www.r-project.org). 
Histological analysis of human biopsies: FFPE blocks were sectioned at a thickness of 
4μm and a positive control was added on the right side of the slides. All immunostainings 
were fully calibrated on a Benchmark XT staining module (Ventana Medical Systems Inc., 
USA). Briefly, after sections were dewaxed and rehydrated, a   CC1 Standard Benchmark 
XT pretreatment for antigen retrieval (Ventana Medical Systems) was selected for all 
immunostainings: Chromogranin A (1:500, Dako, Denmark), Synaptophysin, (1:200, Life 
Technologies, Invitrogen, USA), GAST, CGC and STT. Detection was performed with 
iView DAB Detection Kit (Ventana Medical Systems Inc., USA) and counterstained with 
hematoxylin (Ventana Medical Systems Inc., USA). After the run on the automated stainer 
was completed, slides were dehydrated in ethanol solutions (70%, 96%, and 100%) for one 
min each. Sections were then cleared in xylene for 2 min, mounted with Entellan and cover 
slips were added.    
 
 
Generation of induced pluripotent stem cells (iPSCs) from patient lymphocytes: 
Whole blood was isolated by routine venipuncture from patient 2.1 and two healthy 
siblings (2.3- heterozygous carrier, 2.4- unaffected WT) at Sheba Medical Center in Israel, 
in preservative-free 0.9% sodium chloride containing 100U/ml heparin. Blood was then 
shipped overnight to Cincinnati Children’s Hospital Medical Center for iPS cell generation. 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by Ficoll 
centrifugation as previously described28 and were used to derive iPSCs. Briefly, PBMCs 
were cultured for 4 d in DMEM containing 10% FCS, 100ng/ml SCF, 100ng/ml TPO, 
100ng/ml IL3, 20ng/ml IL6, 100ng/ml Flt3L, 100ng/ml GM-CSF, and 50ng/ml M-CSF 
(Peprotech). Transduction using a polycistronic lentivirus expressing Oct4, Sox2, Klf4, 
cMyc and dTomato was performed31 following the second day of culture in this media. 
Transduced cells were then cultured for an additional 4 d in DMEM containing 10% FCS, 
100ng/ml SCF, 100ng/ml TPO, 100ng/ml IL3, 20ng/ml IL6, and 100ng/ml Flt3L. Media 
was changed every other day. PBMCs were then plated on 0.1% gelatin-coated dishes 
containing 2 ´ 104 irradiated MEFs/cm2 (GlobalStem, Rockville, MD), and cultured in 
hESC media containing 20% knockout serum replacement, 1mM L-glutamine, 0.1mM β-
mercaptoethanol, 1´ non-essential amino acids, and 4ng/ml bFGF until iPSC colony 
formation. Putative iPSC colonies were then manually excised and re-plated in feeder free 
culture conditions consisting of matrigel (BD BioSciences, San Jose, CA) and mTeSR1 
(STEMCELL Technologies, Vancouver, BC). Lines exhibiting robust proliferation and 
maintenance of stereotypical human pluripotent stem cell morphology were then expanded 
and cryopreserved before use in experiments. Standard metaphase spreads and G-banded 
karyotypes were determined by the CCHMC Cytogenetics Laboratory. 
Differentiation of iPSCs into intestinal organoids: The differentiation of induced human 
pluripotent stem cells was performed as previously described13,32,33 with minor 
modifications. Briefly, two clonal iPSC lines from each donor were dispase passaged into 
a matrigel-coated 24-well tissue culture plate and cultured for 3 d in mTeSR1.  Following 
definitive endoderm differentiation, the monolayers were treated for 4 d with RPMI 
medium 1640 (Gibco) containing 2% defined fetal calf serum, 1´ non-essential amino 
acids, 3µM CHIR99021 (Stemgent) and 500ng/ml rhFGF4 (R&D Systems) to induce 
hindgut spheroid morphogenesis.  After the 4th day, “day 0” HIOs were collected and 
 
 
embedded in matrigel matrix and cultured in Advanced DMEM/F12 (Gibco) containing 
100 U/ml penicillin/streptomycin (Gibco), 2mM L-Glutamine (Gibco), 15mM HEPES 
(Gibco), N2 Supplement (Gibco), B27 Supplement (Gibco), and 100ng/mL rhEGF (R&D 
Systems) for up to 42 days, splitting, passaging, and changing the media periodically. 
HIOs collected for immunofluorescence analysis were fixed in 4% paraformaldehyde for 
1-2 h at room temperature, washed overnight at 4°C in PBS, and embedded in O.C.T. 
Compound (Sakura). 8-10µm thick sections were incubated with primary antibodies 
overnight at 4°C in 10% normal donkey serum, 0.05% Triton X-100-PBS solution and 
subsequently incubated with secondary antibodies for 1 h at room temperature.  The 
primary antibodies used were:  FoxA2 (1:500; Novus), E-Cadherin (1:500; R&D Systems), 
Synaptophysin (1:1000; Synaptic Systems), CDX2 (1:500; Biogenex), Pdx1 (1:5000; 
Abcam).  All secondary antibodies (AlexaFluor; Invitrogen) were used at 1:500 dilution.  
Confocal microscopy images were captured with a 20´ plan apo objective on a Nikon 
A1Rsi Inverted, using settings of 0.5 pixel dwell time, 1024 resolution, 2´ line averaging, 
and 2.0´ A1 plus scan. 
Total RNA was extracted from HIOs using a NucleoSpin RNA II kit (Macherey-Nagel), 
and cDNA was synthesized with SuperScript VILO (Invitrogen) using 300ng RNA.  qPCR 
analysis was performed with TaqMan Fast Advanced Master Mix and custom designed 
TaqMan Array 96-Well FAST Plates (Applied Biosystems) consisting of the following 
targets:  18S-Hs99999901_s1; GAPDH-Hs99999905_m1; ARX-Hs00292465_m1; 
CHGA-Hs00900370_m1; SYP-Hs00300531_m1; NTS-Hs00175048_m1. 
  
 
 
Supplementary Information is available in the online version of the paper. 
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